Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2014 Oct;14(5):335-42.
doi: 10.1016/j.clml.2014.01.007. Epub 2014 Feb 7.

Status of PI3K/Akt/mTOR pathway inhibitors in lymphoma

Jason R Westin  1
Affiliations
Review

Status of PI3K/Akt/mTOR pathway inhibitors in lymphoma

Jason R Westin. Clin Lymphoma Myeloma Leuk. 2014 Oct.

Abstract

The phosphatidylinositol-3-kinase (PI3K) pathway is well known to regulate a wide variety of essential cellular functions, including glucose metabolism, translational regulation of protein synthesis, cell proliferation, apoptosis, and survival. Aberrations in the PI3K pathway are among the most frequently observed in cancer, and include amplifications, rearrangements, mutations, and loss of regulators. As a net result of these anomalies, the PI3K pathway is activated in many malignancies, including in Hodgkin and non-Hodgkin lymphomas, and yields a competitive growth and survival advantage, increased metastatic ability, and resistance to conventional therapy. Numerous inhibitors targeting various nodes in the PI3K pathway are undergoing clinical development, and their current status in lymphoma will be the focus of this review.

Keywords: Akt; Lymphoma; PI3K; Review; Signalling; Targeted; Therapy; mTor.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Class I PI3K Family Proteins
Figure 2
Figure 2
PI3K/Akt/mTOR Overview and Targets
See this image and copyright information in PMC

References

    1. Engelman JA. Targeting PI3K signalling in cancer: opportunities, challenges and limitations. Nat Rev Cancer. 2009;9:550–62. - PubMed
    1. Yuan TL, Cantley LC. PI3K pathway alterations in cancer: variations on a theme. Oncogene. 2008;27:5497–510. - PMC - PubMed
    1. Hennessy BT, Smith DL, Ram PT, Lu Y, Mills GB. Exploiting the PI3K/AKT pathway for cancer drug discovery. Nat Rev Drug Discov. 2005;4:988–1004. - PubMed
    1. Huang CH, Mandelker D, Schmidt-Kittler O, et al. The structure of a human p110α/p85α complex elucidates the effects of oncogenic PI3Kα mutations. Science. 2007;318:1744–8. - PubMed
    1. Vivanco I, Sawyers CL. The phosphatidylinositol 3-kinase AKT pathway in human cancer. Nat Rev Cancer. 2002;2:489–501. - PubMed

MeSH terms